Pacira publishes two-year Phase 1 data for knee OA gene therapy

August 6, 2026 8:00 AM

Pacira BioSciences (NASDAQ: PCRX) announced the publication of two-year Phase 1 clinical trial results for its investigational gene therapy PCRX-201 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found